These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34617326)

  • 1. Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.
    Robles-Valero J; Fernández-Nevado L; Lorenzo-Martín LF; Cuadrado M; Fernández-Pisonero I; Rodríguez-Fdez S; Astorga-Simón EN; Abad A; Caloto R; Bustelo XR
    EMBO J; 2021 Nov; 40(22):e108125. PubMed ID: 34617326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
    Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
    Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fusion oncogene VAV1-MYO1F triggers aberrant T-cell receptor signaling in vivo and drives peripheral T-cell lymphoma in mice.
    Morrish E; Wartewig T; Kratzert A; Rosenbaum M; Steiger K; Ruland J
    Eur J Immunol; 2023 Mar; 53(3):e2250147. PubMed ID: 36541400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Fukumoto K; Sakata-Yanagimoto M; Fujisawa M; Sakamoto T; Miyoshi H; Suehara Y; Nguyen TB; Suma S; Yanagimoto S; Shiraishi Y; Chiba K; Bouska A; Kataoka K; Ogawa S; Iqbal J; Ohshima K; Chiba S
    Blood; 2020 Dec; 136(26):3018-3032. PubMed ID: 32992343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.
    Abate F; da Silva-Almeida AC; Zairis S; Robles-Valero J; Couronne L; Khiabanian H; Quinn SA; Kim MY; Laginestra MA; Kim C; Fiore D; Bhagat G; Piris MA; Campo E; Lossos IS; Bernard OA; Inghirami G; Pileri S; Bustelo XR; Rabadan R; Ferrando AA; Palomero T
    Proc Natl Acad Sci U S A; 2017 Jan; 114(4):764-769. PubMed ID: 28062691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.
    Robles-Valero J; Fernández-Nevado L; Cuadrado M; Lorenzo-Martín LF; Fernández-Pisonero I; Abad A; Redín E; Montuenga L; Martín-Zanca D; Bigas A; Mallo M; Dosil M; Bustelo XR
    Mol Oncol; 2022 Oct; 16(19):3533-3553. PubMed ID: 35895495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol Monophosphates Regulate Optimal Vav1 Signaling Output.
    Rodríguez-Fdez S; Citterio C; Lorenzo-Martín LF; Baltanás-Copado J; Llorente-González C; Corbalán-García S; Vicente-Manzanares M; Bustelo XR
    Cells; 2019 Dec; 8(12):. PubMed ID: 31888228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine Acetylation Reshapes the Downstream Signaling Landscape of Vav1 in Lymphocytes.
    Rodríguez-Fdez S; Fernández-Nevado L; Lorenzo-Martín LF; Bustelo XR
    Cells; 2020 Mar; 9(3):. PubMed ID: 32143292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD147 inhibits the nuclear factor of activated T-cells by impairing Vav1 and Rac1 downstream signaling.
    Ruiz S; Castro-Castro A; Bustelo XR
    J Biol Chem; 2008 Feb; 283(9):5554-66. PubMed ID: 18160397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Fujisawa M; Sakata-Yanagimoto M; Nishizawa S; Komori D; Gershon P; Kiryu M; Tanzima S; Fukumoto K; Enami T; Muratani M; Yoshida K; Ogawa S; Matsue K; Nakamura N; Takeuchi K; Izutsu K; Fujimoto K; Teshima T; Miyoshi H; Gaulard P; Ohshima K; Chiba S
    Leukemia; 2018 Mar; 32(3):694-702. PubMed ID: 28832024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex.
    Brooun A; Foster SA; Chrencik JE; Chien EY; Kolatkar AR; Streiff M; Ramage P; Widmer H; Weckbecker G; Kuhn P
    Protein Expr Purif; 2007 May; 53(1):51-62. PubMed ID: 17275330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vav1 GEF activity is required for T cell mediated allograft rejection.
    Haubert D; Li J; Saveliev A; Calzascia T; Sutter E; Metzler B; Kaiser D; Tybulewicz VL; Weckbecker G
    Transpl Immunol; 2012 Jun; 26(4):212-9. PubMed ID: 22456277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity.
    Lazer G; Pe'er L; Farago M; Machida K; Mayer BJ; Katzav S
    J Biol Chem; 2010 Jul; 285(30):23075-85. PubMed ID: 20457609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.
    Robles-Valero J; Lorenzo-Martín LF; Menacho-Márquez M; Fernández-Pisonero I; Abad A; Camós M; Toribio ML; Espinosa L; Bigas A; Bustelo XR
    Cancer Cell; 2017 Nov; 32(5):608-623.e9. PubMed ID: 29136506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell LFA-1 engagement induces HuR-dependent cytokine mRNA stabilization through a Vav-1, Rac1/2, p38MAPK and MKK3 signaling cascade.
    Ramgolam VS; DeGregorio SD; Rao GK; Collinge M; Subaran SS; Markovic-Plese S; Pardi R; Bender JR
    PLoS One; 2010 Dec; 5(12):e14450. PubMed ID: 21206905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct functions of Vav1 in JNK1 activation in Jurkat T cells versus non-haematopoietic cells.
    Kaminski S; Del Pozo MA; Hipskind RA; Altman A; Villalba M
    Scand J Immunol; 2004 Jun; 59(6):527-35. PubMed ID: 15182247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1.
    Razidlo GL; Wang Y; Chen J; Krueger EW; Billadeau DD; McNiven MA
    Dev Cell; 2013 Mar; 24(6):573-85. PubMed ID: 23537630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of the nucleotide exchange activity of vav1 in T cell development and activation.
    Saveliev A; Vanes L; Ksionda O; Rapley J; Smerdon SJ; Rittinger K; Tybulewicz VL
    Sci Signal; 2009 Dec; 2(101):ra83. PubMed ID: 20009105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of Sam68 with Vav1 contributes to tumorigenesis.
    Lazer G; Pe'er L; Schapira V; Richard S; Katzav S
    Cell Signal; 2007 Dec; 19(12):2479-86. PubMed ID: 17855053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vav1-mediated scaffolding interactions stabilize SLP-76 microclusters and contribute to antigen-dependent T cell responses.
    Sylvain NR; Nguyen K; Bunnell SC
    Sci Signal; 2011 Mar; 4(163):ra14. PubMed ID: 21386095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.